Scinai Immunotherapeutics Ltd
SCNI1.510USD
+0.040+2.72%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
1.29MMarktkapitalisierung
0.34KGV TTM
mehr Informationen über Scinai Immunotherapeutics Ltd Unternehmen
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Unternehmensinformationen
BörsenkürzelSCNI
Name des UnternehmensScinai Immunotherapeutics Ltd
IPO-datumJun 07, 2007
CEOMr. Amir Reichman
Anzahl der mitarbeiter31
WertpapierartDepository Receipt
GeschäftsjahresendeJun 07
AddresseJerusalem Biopark, 2Nd Floor
StadtJERUSALEM
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl00000
Telefon97289302529
Websitehttps://www.scinai.com/
BörsenkürzelSCNI
IPO-datumJun 07, 2007
CEOMr. Amir Reichman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+51.52%
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Mr. Joshua Phillipson
Mr. Joshua Phillipson
Investor Relations
Investor Relations
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, May 28
Aktualisiert: Wed, May 28
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Aktionäre
Aktionäre
Anteil
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
14.34%
Corporation
9.47%
Individual Investor
8.75%
Investment Advisor
6.93%
Hedge Fund
5.25%
Research Firm
0.02%
Other
55.24%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
32
381.87K
44.77%
+269.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
2023Q2
41
94.79K
37.87%
-787.00
2023Q1
43
111.61K
43.64%
+31.95K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Yorkville Advisors Global, LP.
93.27K
10.93%
+93.27K
--
Mar 24, 2025
LCK JNK 1 LLC
80.76K
9.47%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
62.40K
7.32%
--
--
Dec 31, 2024
Armistice Capital LLC
44.80K
5.25%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
4.99%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
3.41%
+29.05K
--
Dec 31, 2024
UBS Financial Services, Inc.
14.93K
1.75%
-8.56K
-36.43%
Mar 31, 2025
Reichman (Amir)
8.08K
0.95%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.57K
0.18%
-86.00
-5.20%
Mar 31, 2025
Ben-Yedidia (Tamar)
1.35K
0.16%
+1.35K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Datum
Art
Verhältnis
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
